İnflamatuar Meme Kanseri: Klinik, Moleküler Özellikler ve Güncel Tedavi Yaklaşımları

Chippa V, Barazi H. Inflammatory Breast Cancer. [Updated 2023 Apr 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.

Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar;27(3):359-66.

van Uden DJ, van Laarhoven HW, Westenberg AH, de Wilt JH, Blanken-Peeters CF. Inflammatory breast cancer: an overview. Crit Rev Oncol Hematol. 2015 Feb;93(2):116-26.

Faldoni FLC, Villacis RAR, Canto LM, Fonseca-Alves CE, Cury SS, Larsen SJ, Aagaard MM, Souza CP, Scapulatempo-Neto C, Osório CABT, Baumbach J, Marchi FA, Rogatto SR. Inflammatory Breast Cancer: Clinical Implications of Genomic Alterations and Mutational Profiling. Cancers (Basel). 2020 Sep 30;12(10).

Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, Reed BJ, Yang WT. MRI features of inflammatory breast cancer. AJR Am J Roentgenol. 2011 Oct;197(4):W769-76.

Priedigkeit N, Harrison B, Shue R, Hughes ME, Li Y, Lebrón-Torres A, Kirkner GJ, Spurr LF, Remolano MC, Strauss S, Files J, Feeney AM, Grant L, Mohammed-Abreu A, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, Nakhlis F, Bellon JR, King TA, Winer EP, Lindeman N, Johnson BE, Sholl L, Dillon D, Overmoyer B, Tolaney SM, Cherniack AD, Lin NU, Lynce F. Clinicogenomic characterization of inflammatory breast cancer. Clin Cancer Res. 2025;31(14):3072-3083. doi:10.1158/1078-0432.CCR-24-2081.

Di Bonito M, et al. Pathological and molecular characteristics of inflammatory breast cancer: a comprehensive review. Int J Mol Sci. 2021;22(5):2279.

Zhao YC, et al. Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. World J Surg Oncol. 2012;10:165.

Jagsi R, King TA, Lehman C, Morrow M. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res Treat. 2022;192(3):433-442.

Shah M, Rosner GL, Rastogi P, Huynh L, Ghamande S, Unger EF, et al. FDA Approval Summary: Pembrolizumab for Neoadjuvant Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res. 2022;28(17):3748-53. doi:10.1158/1078-0432.CCR-22-0835.

Wahby S, Fashoyin-Aje L, Osgood CL, Cheng J, Fiero MH, Zhang L, et al. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. Clin Cancer Res. 2021;27(7):1850-4. doi:10.1158/1078-0432.CCR-20-3119.

Takahashi Y, Sridhar N, Iwase T, Woodward WA. Inflammatory breast cancer, best practice in the community setting. npj Breast Cancer. 2025;11(1). doi:10.1038/s41523-025-00765-4.

National Comprehensive Cancer Network. NCCN Guidelines for Patients: Inflammatory Breast Cancer. Plymouth Meeting (PA): NCCN; 2025.

Loibl S, André F, Bachelot T, Curigliano G, Denkert C, Delaloge S, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159-182. doi:10.1016/j.annonc.2023.11.016.

Schmid P, Dent R, O’Shaughnessy J, Pusztai L, McArthur HL, Kümmel S, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024;391:1636-1648. doi:10.1056/NEJMoa2409932.

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690.